Wells Fargo has recently initiated Exact Sciences Corp (EXAS) stock to Overweight rating, as announced on August 28, 2024, according to Finviz. Earlier, on June 27, 2024, Scotiabank had initiated the ...

Analyst Price Forecast Suggests 28.14% Upside As of August 26, 2024, the average one-year price target for Exact Sciences is $78.36/share. The forecasts range from a low of $60.60 to a high of ...

MADISON, Wis., August 28, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited ...

This story was originally printed in today’s (Nov. 7) Daily Post. To get important local news first, pick up the Post at 1,000 Mid-Peninsula locations. By the Daily Post staff […] Only a fraction of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Exact Sciences EXAS continues to make significant progress with its Cologuard test and efforts to expand Oncotype DX overseas. Advancements in the key pipeline programs are highly promising.

Ji Nam covers the Healthcare sector, focusing on stocks such as Quanterix, Exact Sciences ... Talasaz in 2012 and is headquartered in Redwood City, CA. Read More on GH: Guardant Health NewsMORE ...

Baron Opportunity Fund highlighted stocks like Exact Sciences Corporation (NASDAQ:EXAS) in the second quarter 2024 investor letter. Exact Sciences Corporation (NASDAQ:EXAS) provides cancer ...

MADISON - Exact Sciences Corp. (NASDAQ:EXAS), a prominent player in cancer screening and diagnostics, announced the commencement of its Falcon Registry study for Multi-Cancer Early Detection (MCED) at ...